Keynote-240 . Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients. January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients. January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Keynote-240 Images References :
Source: oncologiabrasil.com.br
Estudo KEYNOTE240 pembrolizumabe em segunda linha para , January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Source: www.sohu.com
文献速递（第340期）—Pembrolizumab（派姆单抗）作为中晚期肝癌患者的二线治疗的KEYNOTE240研究_索拉非尼 , Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients.
Source: www.youtube.com
Estudo KEYNOTE240 pembrolizumabe em segunda linha para , Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients.
Source: www.researchgate.net
Main characteristics from KEYNOTE240 and KEYNOTE394 Download , January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Source: www.researchgate.net
(PDF) Pembrolizumab as SecondLine Therapy for Advanced Hepatocellular , January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Source: www.sohu.com
帕博利珠单抗治疗晚期HCC——KEYNOTE240延长18个月的随访数据公布_患者_研究_分析 , January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Source: asco.ioncol.com
ASCO2019 美国临床肿瘤协会年会 , January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Source: www.researchgate.net
(PDF) ALBI score and in patients with hepatocellular carcinoma , January 17, 2021—pembrolizumab improved survival, compared with placebo, in patients with previously treated advanced hepatocellular carcinoma, according to updated.
Source: www.researchgate.net
(PDF) Is the "Pvalue" Alone a Sufficient Metric for the Magnitude of , Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients.
Source: slideplayer.com
State of the Art in HCC Immune Checkpoint Modulation ppt download , Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients.
Continue Reading